2 results
Approved WMORecruiting
To evaluate the safety and tolerability of treatment with atogepant 60 mg once daily when administered over 156 weeks for the prevention of migraine in participants with Chronic Migraine (CM) or Episodic Migraine (EM).
Approved WMOSuspended
The primary objective of the study is survival on a Carmat device at 180 days post-implant* or survival to cardiac transplantation if occurring before 180 days post-implant**. * The beginning of the implant procedure is defined as the start of theā¦